Analyst Justin Keywood from Stifel Nicolaus maintained a Hold rating on Medexus Pharmaceuticals Inc (MDP – Research Report) and decreased the price target to C$3.45 from C$6.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Justin Keywood has given his Hold rating due to a combination of factors, despite Medexus Pharmaceuticals Inc. showing promising financial growth in recent quarters. The company’s stock has experienced significant gains, largely driven by the recent FDA approval of GRAFAPEX, a treatment for stem cell transplantation. However, concerns about the pricing strategy for GRAFAPEX and the potential impact on profitability have tempered optimism.
Additionally, the company faces challenges such as the loss of exclusivity for Rupall, which constitutes a significant portion of sales, and a setback with Health Canada’s decision on Terbinafine. These elements contribute to uncertainties that may hinder Medexus’s performance in the near term, justifying the Hold rating. The combination of these factors indicates that while there is potential for future growth, there are also risks that need to be considered.
According to TipRanks, Keywood is an analyst with an average return of -5.0% and a 42.62% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, Cipher Pharmaceuticals, and NervGen Pharma.